Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants

Summary

This study is being conducted to demonstrate the effect of Auryxia, when used as the primary phosphate lowering therapy, on the overall cumulative use of erythropoiesis-stimulating agent and intravenous iron as well as on the laboratory parameters indicative of phosphate and anemia management.

Timeline

Start

2021-06-29

Primary completion

2022-09-15

Completion

2022-09-15

Publications

• Natale P, Green SC, Ruospo M, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.
• Block GA, Mizani MR, Broumand V, Newby FD, Erinle A, Arias C, Block M, Brillhart S, Leppink A, Danese M, Dittrich M. A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis. Am J Nephrol. 2024;55(5):520-528. doi: 10.1159/000540227. Epub 2024 Jul 15.

Drugs

Indications